Limerston exits Prism to Charme

Charme has bought the asset from its Charme IV fund, which launched in 2021 and has raised around EUR 700m to date.

Limerston will retain a stake in the company alongside management. It first invested in the asset in 2018 from its debut Limerston Capital Partners I fund.

Charme IV has also acquired Italian lab group Bianalisi and invested a minority stake in UK children's and education provider Witherslack after selling the asset to Mubadala.

Prism develops, delivers, installs and services equipment to public authorities and private providers to help disabled and mobility disadvantaged people remain mobile.

The asset doubled its size and completed four add-on acquisitions under Limerston's ownership.

Charme will support Prism's organic growth through the development of its offering, as well as via acquisitions in the UK and internationally.

Advisors
Limerston - Baird (M&A); Weil, Gotshal & Manges (legal), KPMG (due diligence).

Charme - Houlihan Lokey (M&A); Mcfarlanes (legal); PwC (due diligence).

The company
Headquartered in Wakefield, Yorkshire, Prism Healthcare has a diverse portfolio of UK manufactured equipment, including safe patient handling, bathing, accessibility and pressure area care products.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• UK / Ireland
• Buyouts
• healthcare